Sanofi is requesting a Dengvaxia label change that will likely lead to fewer eligible recipients.
Pfizer's Prevnar 13 is set for another price hike in 2018, according to Kaiser Health News.
A study published in Pediatrics showed that protection of Merck's Gardasil lasts over 10 years.
Here is some other vaccine news of note for the week.
With financial support from BARDA, Takeda's purified, inactivated, alum-adjuvanted Zika vaccine has entered human testing.
Before heading offshore for a dubious herpes vaccine trial, a Southern Illinois University did such experiments on people in the U.S.
Despite a frantic effort to rush Ebola vaccines through testing during an epidemic, Merck will fall short in its goal to file its candidate this year.
As Emergent BioSolutions pushes toward its goal of reaching $1 billion in annual revenues, the company has secured an important regulatory milestone.
Immunovaccine and Leidos are working together to determine the most promising malaria vaccine formulations.